ArticleFrontiers in oncology2025
Deciphering the circadian rhythm in colorectal cancer: a bibliometric analysis of research landscape and trends.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of circadian rhythm-related genes in colorectal cancer by integrating bioinformatics and multi-omics mendelian randomization.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Colorectal cancer (CRC) is a leading cause of global cancer mortality, increasingly linked to circadian rhythm disruption-a critical yet underexplored driver of tumorigenesis. Methods: This bibliometric analysis evaluates 374 publications from the Web of Science Core Collection (1999-2024) using VOSviewer, CiteSpace, and Bibliometrix to map global research trends. Results: Annual publications surged post-2016, peaking in 2021, reflecting intensified focus on circadian-CRC interactions. The United States led in output (122 publications, H-index 46), followed by France (76 publications) and China (49 publications), with the Netherlands achieving the highest citation impact (88.06 citations per publication). French institutions, notably Assistance Publique-Hôpitaux de Paris (APHP), dominated translational research, while foundational studies by Levi et al. on chronomodulated chemotherapy remained pivotal. Keyword analysis identified "circadian rhythm" and "colorectal cancer" as core themes, with "inflammation" and "inflammatory bowel disease" showing significant citation bursts post-2014. Co-citation networks bridged molecular chronobiology (Science, PNAS) and clinical oncology (Cancer Research), though mechanistic studies prioritized clock genes (e.g., BMAL1, PER2) over environmental disruptors. Clinically, aligning chemotherapy with circadian rhythms reduced severe toxicity by 40% in metastatic CRC, yet gaps persist in biomarker validation and monitoring tools. Epidemiologically, shift workers faced a 20-30% elevated CRC risk, correlating with PER2 silencing in 45% of tumors and NF-κB/STAT3 pathway activation. Discussion: Future research should integrate AI-driven circadian profiling, global collaboration, and trials targeting circadian-immune-metabolic axes to advance precision chronotherapy. This study underscores circadian biology as a cornerstone of CRC management, advocating strategies that harmonize molecular insights with ecological relevance to improve outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.